Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation

• DOI: 10.1111/jgh.12403
• Publication Date: 2013-10-12T02:45:41Z
• Authors: Gun Hyung Na; Dong Goo Kim; Jae Hyun Han; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You; Jong Young Choi
• Keywords: Entecavir; Hepatitis B; Liver disease

Without effective prophylaxis, liver transplantation (LT) for hepatitis B virus (HBV)-related disease is frequently complicated by severe and rapidly progressive HBV recurrence. The combination of low-dose immunoglobulin (HBIG) the new nucleos(t)ide analog, entecavir, as prophylaxis recurrence after living-donor LT (LDLT) were analyzed.A total 315 patients with positive surface antigen underwent LDLT at our transplant center between July 2003 December 2011. Our protocol post-transplantation was a HBIG analog.During median follow-up period 49 months post-transplant, 10 (3.2%) had recurrence, which significantly related to hepatocellular carcinoma (HCC) (P = 0.041) post-LT antiviral agent < 0.001) in multivariate analysis. level DNA e state not significant factors 0.342 P 0.802, respectively). In 170 HCC LDLT, 0.001). Among three are alive two lost antigen. remaining seven died recurrence.The analogs safe LDLT. As treatment, entecavir more than lamivudine. associated HBV-related who undergo require close virological monitoring.